Triple-Negative Breast Cancer: A New Hope with AR Antagonists and PARP1 Inhibitors?
"Targeting AR Expression and BRCA1 Dysfunction Shows Promise in Sporadic TNBC Treatment"
Triple-negative breast cancer (TNBC) is a challenging diagnosis, accounting for 15-20% of all breast cancers. Known for its aggressive nature, TNBC is characterized by rapid growth, early metastasis, and a higher risk of recurrence. Unlike other breast cancers, TNBC lacks estrogen receptors (ER), progesterone receptors (PR), and human epidermal growth factor receptor-2 (HER2), making it unresponsive to common hormone therapies.
Traditional treatment options for TNBC are limited, often relying on chemotherapy regimens that can be harsh and have varying degrees of success. This is because TNBC is not a single disease, but rather a collection of subtypes, each with unique characteristics and responses to treatment. Identifying these subtypes and developing targeted therapies is crucial for improving outcomes for women diagnosed with TNBC.
Recent research has focused on the role of the androgen receptor (AR) in TNBC. While AR is typically associated with male hormones, it is expressed in a significant percentage of TNBC tumors (15-50%). The presence of AR has sparked debate about its role in cancer progression and whether it can be a target for therapy. Studies suggest that blocking AR, particularly in combination with other agents, may offer a new approach to treating specific TNBC subtypes.
TNBC Burden and Treatment Gap
Triple-negative breast cancer (TNBC) lacks expression of estrogen receptors (ER), progesterone receptors (PR), and human epidermal growth factor receptor 2 (HER2). Around 15–20% of all breast cancers are diagnosed as TNBC, according to Susan G. Komen. Its survival rate is generally worse than that of other breast cancer subtypes, and it has high recurrence rates and a poor prognosis. Current treatment options remain limited because TNBC does not respond to hormone therapy and has relatively few targeted therapies.
Conventional Treatment and AR Targeting
TNBC is clinically aggressive and highly heterogeneous at the molecular and genetic levels. Conventional treatment has been limited by marked resistance to chemotherapy regimens, while current standard-of-care approaches focus largely on chemotherapy and immunotherapy. The androgen receptor (AR) has therefore emerged as a potential target in the subset of TNBC tumors that express it. Reviews identify antiandrogens as a central strategy for AR-positive TNBC within an increasingly precision-oriented treatment approach.
From Chemotherapy to Molecular Targets
TNBC is defined by the absence of ER, PR, and HER2, the three main cellular markers used to guide contemporary breast cancer treatment. Population and epidemiological data place TNBC at approximately 10% to 20% of all breast cancers. Until recently, cytotoxic chemotherapy was the mainstay of treatment. The field subsequently developed toward molecularly targeted strategies as researchers sought alternatives for this biologically distinct and clinically challenging subtype.
AR and BRCA1: Unlocking the Keys to TNBC Treatment
A groundbreaking study published in Biomedicine & Pharmacotherapy sheds light on the potential of targeting AR in combination with PARP1 inhibitors for the treatment of sporadic TNBC. The study, led by Meixiang Sang and colleagues, investigated the expression of AR and BRCA1 in TNBC tissues and explored the effects of AR blockade and PARP1 inhibition on cancer cell growth.
- AR Expression: The study found AR expression in 43.6% and 34.0% of TNBC tissues using 1% or 10% staining thresholds, respectively.
- Prognostic Role: AR expression, when using a 1% threshold, was linked to poorer disease-free survival (DFS) in TNBC patients.
- BRCA1 Impact: Negative BRCA1 expression also correlated with poor DFS, and BRCA1 suppression was linked to promoter methylation.
- Combined Effect: BRCA1-/AR+ TNBC patients experienced shorter DFS than other TNBC patients, regardless of AR positivity threshold.
AR and PARP1 Combination Research
A 2019 study by Sang and colleagues examined an AR antagonist combined with a PARP1 inhibitor in sporadic TNBC bearing AR expression and methylation-mediated BRCA1 dysfunction. Research has also investigated PARP-1 and AR as immunohistochemical markers with possible relevance to TNBC treatment. A 2025 molecular-subtyping study reported that BRCA1 expression correlated negatively with AR and PARP expression, suggesting that combined PARP and AR inhibition could be explored for AR-positive and BRCA1-inactivated TNBC. Reviews published in 2025 likewise describe AR-targeted therapy as a promising area requiring further clinical exploration.
Persistent Clinical Challenges
TNBC remains difficult to treat because of its aggressive nature, limited treatment options, and poorer prognosis compared with other breast cancer subtypes. Treatment advances have occurred, but important limitations remain. The disease's biological heterogeneity and resistance to available therapies complicate the development of consistently effective treatment strategies. These challenges temper enthusiasm for emerging approaches, including AR antagonists and PARP1 inhibitors, until their benefits are established more broadly.
A Glimmer of Hope for TNBC Patients
This research offers a promising avenue for developing more effective treatments for sporadic TNBC, particularly for patients whose tumors express AR and exhibit BRCA1 dysfunction. By combining AR blockade with PARP1 inhibition, clinicians may be able to target the unique vulnerabilities of these cancer cells, leading to improved outcomes and a better quality of life for women facing this challenging diagnosis. Further research, including clinical trials, is needed to validate these findings and translate them into clinical practice. However, this study provides a crucial step forward in the ongoing quest to conquer triple-negative breast cancer.
Patient Outcomes and Treatment Benefit
The clinical importance of AR expression is being assessed through its relationship with disease-free survival and overall survival in patients with TNBC. A systematic review and meta-analysis specifically evaluated the prognostic impact of AR protein expression. Antiandrogens have also been tested in clinical trials involving AR-positive TNBC, with real-world research assessing the clinical benefit rate at six months. These findings reflect both the need for individualized treatment and the uncertainty surrounding how consistently antiandrogen therapy benefits patients in routine care.